About Halia Therapeutics
Halia Therapeutics is a private company based in Lehi, Utah. It has reported $27,391,629 raised in five offerings on Form D since October 2020. Its chief executive is David Bearss.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Aug 31, 2026 | $3,486,474of $20.0M target | 9 | $387K | Equity, Options, Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Jul 1, 2025 | Jul 16, 2025 | $336,833of $19.9M target | 5 | $67,367 | EquityRule 506(b) | Form D ↗ |
| Dec 16, 2022 | Dec 30, 2022 | $12,223,338of $49.9M target | 24 | $509K | EquityRule 506(b) | Form D ↗ |
| Feb 3, 2021 | Feb 17, 2021 | $4,999,994of $5.0M target | 5 | $999K | EquityRule 506(b) | Form D ↗ |
| Oct 9, 2020 | Oct 22, 2020 | $6,344,990of $15.0M target | 9 | $704K | Equity, OptionsRule 506(b) | Form D ↗ |
| Total, five offerings | $27,391,629 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Halia Therapeutics's Form D filed Aug 31, 2026.
Preston Campbell
Director
MB
Mary Beckerle
Director
David Checketts
Director
Gary Sabin
Executive Chairman
David Bearss
Chief Executive Officer and director
Also a co-founder · chairman at Biolexis Therapeutics and a director at Canary Speech and Reglagene.
John Kauwe
Co-Founder and director
Earlier filings also listed Todd Pedersen (director, last listed Jul 2025), Jim Savas (director, last listed Jul 2025), Jared Bearss (director, last listed Jul 2025) and Mike McCullar (executive officer and director, last listed Feb 2021).